Web Results

Cladribine - Wikipedia


Cladribine is a medication used to treat hairy cell leukemia (HCL, leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. Its chemical name is ...

Cladribine - Drug Information - Chemocare


(KLA-drih-bean). Trade name: Leustatin<sup>TM</sup> Other names: 2-CdA, 2- Chlorodeoxyadenosine. Cladribine is the generic name for the trade name drug Leustatin<sup>TM</sup>.

Cladribine - FDA prescribing information, side effects and uses


WARNING: Cladribine injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy.

Cladribine (2-CDA, Leustatin®) | OncoLink


Sep 11, 2015 ... Cladribine is a type of chemotherapy that belongs to a class of drugs called antimetabolites. These medications are taken up by cells and are ...

Cladribine (Leustat, Litak) | Cancer Research UK


Dec 16, 2015 ... Read about the cancer treatment drug cladribine, also called LITAK and Leustat, including what it is, how it works and possible side effects.

Cladribine: MedlinePlus Drug Information


Jun 15, 2016 ... Cladribine injection must be given in a hospital or medical facility under the supervision of a doctor who is experienced in giving chemotherapy ...

Cladribine - DrugBank


Cladribine differs structurally from deoxyadenosine only by the presence of a chlorine atom at position 2 of the purine ring, which results in resistance to ...

Cladribine (Leustat ®, LITAK ®) - Cancer Information - Macmillan ...


Find out more about cladribine (Leustat ®, LITAK ®), a chemotherapy drug used to treat hairy cell leukaemia and B-cell chronic lymphocytic leukaemia (CLL)

Cladribine | C10H12ClN5O3 - PubChem


Cladribine is a purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting ...

Cladribine | MS Trust


Oct 2, 2015 ... Cladribine is a cancer drug studied for use as a disease modifying drug in relapsing remitting MS, but it was not approved by drug regulators.